
<p>Ikerian AG (formerly RetinAI Medical AG) is a fast-growing digital healthcare company headquartered in Bern, Switzerland, focused on developing healthcare solutions to generate and organise insights and knowledge, enhance clinical diagnostics and pharmaceutical R&D. Improving patient outcomes and quality of life through innovation and working together with colleagues who love what they do is what gets us up every morning.</p><p>Both idealistic and pragmatic, we are passionate and execution-driven entrepreneurs who are striving to make an impact. In our daily work, we love to tackle challenges, value collaboration and speed in execution and create an environment where no day is the same.</p>

<p>Ikerian AG (formerly RetinAI Medical AG) is a fast-growing digital healthcare company headquartered in Bern, Switzerland, focused on developing healthcare solutions to generate and organise insights and knowledge, enhance clinical diagnostics and pharmaceutical R&D. Improving patient outcomes and quality of life through innovation and working together with colleagues who love what they do is what gets us up every morning.</p><p>Both idealistic and pragmatic, we are passionate and execution-driven entrepreneurs who are striving to make an impact. In our daily work, we love to tackle challenges, value collaboration and speed in execution and create an environment where no day is the same.</p>
Founded: December 2016 (Bern, Switzerland)
Headquarters: Bern, Switzerland (with U.S. presence in Boston, MA)
Flagship product: RetinAI Discovery — image & data management platform for ophthalmology (FDA-cleared 510(k) and CE-marked)
Funding highlights: Pre-Series A CHF 2.3M (2019); Series A Extension USD 6.18M (May 2024); Series B first close USD 8M (Oct 2024); company reported USD 11.66M raised across Seed/Series A/Extension as of May 2024
Exit / M&A: Acquired by EssilorLuxottica (announced 15 Oct 2025)
Ophthalmology (retinal imaging, clinical workflows, research and pharmaceutical RWE analysis).
2016
Digital health / Medical software (Ophthalmology)
CHF 2.3M
Participation from Investiere and selected private investors
USD 6.18M (CHF 5.65M)
Company reported total of USD 11.66M raised across Seed, Series A and Series A Extension as of this date; Zürcher Kantonalbank participated in a first close in 2023
USD 8M (CHF 6.73M)
Participation from existing investors
“Investor base includes strategic corporate investors and European VCs: Sanoptis (Series B lead), THINC Ventures (Topcon Healthcare CVC), Zürcher Kantonalbank (ZKB), Verve Ventures, btov Partners, Investiere, and other private investors; company was acquired by EssilorLuxottica (announced 15 Oct 2025).”
| Company |
|---|
Ikerian AG (formerly RetinAI Medical) is a fast-growing medical device software company headquartered in Bern, Switzerland. Our mission is to enable the right decisions sooner in healthcare, through transformative AI & data management solutions for disease screening and monitoring. Join our diverse team of entrepreneurs, developers, researchers, and commercial experts who are collectively shaping the future of healthcare.
We are looking for a Business Developer to join our team, focused on the Pharma Segment. As a Business Developer you’ll identify new business opportunities in order to generate revenue, improve profitability and help the business grow. Your work will involve careful strategic planning and positioning in the appropriate markets, enhancing the operation of the business and our positioning in the market. The role, reporting to VP Business Development, will be part of a growing team
We are looking for Business Developers with a track record of consultative sales with Ophthalmology Pharma, Biotech , Real World Evidence and / or Clinical Research Organizations (CROs). You will be an independent thinker, a self starter comfortable with ambiguity and a results oriented problem solver.
This role is pivotal in scaling our business development efforts.
Responsibilities:
Skills